NASDAQ:KALA - Nasdaq - US4831192020 - Common Stock - Currency: USD
Overall KALA gets a fundamental rating of 1 out of 10. We evaluated KALA against 556 industry peers in the Biotechnology industry. Both the profitability and financial health of KALA have multiple concerns. KALA has a expensive valuation and it also scores bad on growth.
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -73.89% | ||
ROE | -624.6% | ||
ROIC | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | N/A | ||
PM (TTM) | N/A | ||
GM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 2.65 | ||
Debt/FCF | N/A | ||
Altman-Z | -21.28 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 1.99 | ||
Quick Ratio | 1.99 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | N/A | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
NASDAQ:KALA (7/24/2025, 11:17:39 AM)
6.09
+0.44 (+7.79%)
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A | ||
P/S | N/A | ||
P/FCF | N/A | ||
P/OCF | N/A | ||
P/B | 6.88 | ||
P/tB | 6.88 | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -73.89% | ||
ROE | -624.6% | ||
ROCE | N/A | ||
ROIC | N/A | ||
ROICexc | N/A | ||
ROICexgc | N/A | ||
OM | N/A | ||
PM (TTM) | N/A | ||
GM | N/A | ||
FCFM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 2.65 | ||
Debt/FCF | N/A | ||
Debt/EBITDA | N/A | ||
Cap/Depr | N/A | ||
Cap/Sales | N/A | ||
Interest Coverage | N/A | ||
Cash Conversion | N/A | ||
Profit Quality | N/A | ||
Current Ratio | 1.99 | ||
Quick Ratio | 1.99 | ||
Altman-Z | -21.28 |